Patent intelligence · US
US 10265410
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
Patent details — US 10265410
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 23, 2019
- Expiration
- Apr 18, 2039
- Applicant
- HALOZYME, INC.
- Claims
- 35
- CPC classes
- A61K, A61K31/37, A61K31/42, A61K31/573
Quick answer
US 10265410 (Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects) is held by HALOZYME, INC.. Status: granted. Granted Apr 23, 2019. Expires Apr 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HALOZYME, INC.
- Grant date
- Expiration
- Claims
- 35
- CPC classes
- A61K, A61K31/37, A61K31/42, A61K31/573, A61K38/47, A61K47/60
More from HALOZYME, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421308
Anti-G-CSF antibodies and uses thereof
granted -
US 12371685
PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
granted -
US 12264345
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12195773
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12178860
Hyaluronidase enzyme formulations for high volume administration
granted -
US 12152262
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12123035
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12110520
PH20 polypeptide variants, formulations and uses thereof
granted
Frequently asked questions
What is US patent 10265410?
US 10265410 (Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects) is held by HALOZYME, INC.. Status: granted. Granted Apr 23, 2019. Expires Apr 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10265410?
HALOZYME, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 70 pharmaceutical patents for this assignee.
When does US 10265410 expire?
Our index shows an expiration date of Apr 18, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.